25 October 2023 in Proceedings of the National Academy of Sciences
Messenger RNA (mRNA)–based therapeutics are transforming the landscapes of medicine, yet targeted delivery of mRNA to specific cell types while minimizing off-target accumulation remains challenging for mRNA-mediated therapy. In this study, we report an innovative design of a cationic lipid- and hyaluronic acid–based, dual-targeted mRNA nanoformulation that can display the desirable stability and efficiently transfect the targeted proteins into lung tissues. More importantly, the optimized dual-targeted mRNA nanoparticles (NPs) can not only accumulate primarily in lung tumor cells and inflammatory macrophages after inhalation delivery but also efficiently express any desirable proteins (e.g., p53 tumor suppressor for therapy, as well as luciferase and green fluorescence protein for imaging as examples in this study) and achieve efficacious lung tissue transfection in vivo. Overall, our findings provide proof-of-principle evidence for the design and use of dual-targeted mRNA NPs in homing to specific cell types to up-regulate target proteins in lung tissues, which may hold great potential for the future development of mRNA-based inhaled medicines or vaccines in treating various lung-related diseases.
3 December 2024 in Journal of the American Chemical Society
11 March 2025 in Proceedings of the National Academy of Sciences
Pancreatic ductal adenocarcinoma (PDAC) is notoriously immune-resistant, limiting the clinical efficacy of single-agent immune modulators and thereby necessitating the exploration of multimodal immunotherapy combinations. Traditional approaches combining conventional immune checkpoint inhibitors with neoantigen vaccines have shown some promise in treating PDAC but are often compromised by intratumoral T lymphocyte exhaustion and systemic toxicity. Hence, novel approaches are needed to address these challenges. Herein, we demonstrate that mRNA polymeric nanoparticles encoding anti-PD-1 antibodies in situ at the tumor site enhance the therapeutic efficacy of neoantigen-based mRNA vaccine for PDAC. This mRNA-based, in situ anti-PD-1 antibody production strategy also protects tumor-infiltrating T cells from PD-1 inhibition, potentially reducing the toxicities induced by systemic checkpoint inhibition. Our study may provide an innovative dual mRNA nanoparticle strategy for effective tumor neoantigen immunotherapy, as well as an mRNA cancer combination therapy strategy with other clinically approved drugs (e.g., β-elemene).
12 September 2022 in Advanced Functional Materials
26 February 2024 in Nanoscale
This minireview summarizes the utility of integrating nano-delivery systems with TCM, emphasizing their capacity to enhance treatment efficacy, modernize TCM, and expand global accessibility.
1 January 2026 in Research
Nanozymes overcome key limitations of natural enzymes, including poor environmental tolerance, high production costs, and batch-to-batch variability, with their enhanced physicochemical stability and controllable catalytic performance, thus enabling applications in biocatalysis and disease theranostics. However, their practical applications remain limited by insufficient catalytic efficiency, inadequate target specificity, and restricted programmable dynamic adaptability. DNA nanotechnology offers a versatile and biocompatible framework for the precise regulation of nanozymes due to its sequence-defined programmability and precise molecular recognition capability. This approach improves catalytic performance while maintaining excellent biocompatibility and low immunogenicity. This review systematically summarizes the latest advances in DNA nanotechnology-mediated precise regulation of nanozymes, with particular emphasis on the mechanistic basis of 6 regulatory modes. We further examine the representative applications of these DNA–nanozyme hybrid systems in disease therapy, biomedical sensing, and environmental monitoring, and outline the key challenges and future directions toward clinical and industrial translation.